VIRI Stock Overview
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.95|
|52 Week High||US$16.71|
|52 Week Low||US$4.00|
|1 Month Change||-19.12%|
|3 Month Change||-12.85%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-70.38%|
Recent News & Updates
Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|VIRI||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how VIRI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how VIRI performed against the US Market.
|VIRI Average Weekly Movement||11.5%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: VIRI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: VIRI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020.
Virios Therapeutics Fundamentals Summary
|VIRI fundamental statistics|
Is VIRI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VIRI income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.15|
|Net Profit Margin||0.00%|
How did VIRI perform over the long term?See historical performance and comparison
Is Virios Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VIRI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VIRI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VIRI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: VIRI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VIRI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VIRI is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (2.7x).
How is Virios Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VIRI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VIRI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VIRI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if VIRI's revenue is forecast to grow faster than the US market.
High Growth Revenue: VIRI is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VIRI's Return on Equity is forecast to be high in 3 years time
How has Virios Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: VIRI is currently unprofitable.
Growing Profit Margin: VIRI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if VIRI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare VIRI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VIRI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: VIRI has a negative Return on Equity (-95.07%), as it is currently unprofitable.
How is Virios Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: VIRI's short term assets ($20.1M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: VIRI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: VIRI is debt free.
Reducing Debt: VIRI had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VIRI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VIRI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 85.9% each year
What is Virios Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VIRI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VIRI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VIRI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VIRI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VIRI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Greg Duncan (56 yo)
Mr. Greg Duncan serves as Chief Executive Officer at Virios Therapeutics, Inc., (formerly Virios Therapeutics, LLC) since April 01, 2020 and serves as its Chairman. Mr. Duncan serves as the member of the b...
CEO Compensation Analysis
Compensation vs Market: Greg's total compensation ($USD3.67M) is above average for companies of similar size in the US market ($USD563.50K).
Compensation vs Earnings: Insufficient data to compare Greg's compensation with company performance.
Experienced Management: VIRI's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: VIRI's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: VIRI only recently listed within the past 12 months.
Virios Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Virios Therapeutics, Inc.
- Ticker: VIRI
- Exchange: NasdaqCM
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$42.235m
- Shares outstanding: 8.33m
- Website: https://www.virios.com
Number of Employees
- Virios Therapeutics, Inc.
- 44 Milton Avenue
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/02 23:44|
|End of Day Share Price||2021/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.